NDLI: Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.

Please wait, while we are loading the content...

Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.

Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.

Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.

Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.

Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children.

Muted incentives, omitted variables, and pharmacoeconomic validity: two strikes and you're out!

Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review.

A review of diabetes treatment adherence and the association with clinical and economic outcomes.

Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records.

Medication adherence affects treatment modifications in patients with type 2 diabetes.

Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.

Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects.

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Hines, Lisa E. Ceron-Cabrera, Diana Romero, Klaus Anthony, Marietta Woosley, Raymond L. Armstrong, Edward P. Malone, Daniel C.
Spatial Coverage	United States
Description	Country affiliation: United States Author Affiliation: Hines LE ( Center for Health Outcomes and PharmacoEconomic Research, The University of Arizona College of Pharmacy, Tucson, Arizona 85721-0202, USA.)
Abstract	BACKGROUND: Because interactions with warfarin represent a serious risk to patients, drug information sources used by clinicians should contain accurate, timely, and practical drug interaction information. OBJECTIVE: The aim of this study was to assess the information regarding warfarin interactions that is included in the official labeling of prescription products that interact with warfarin. METHODS: We examined the official labeling information approved by the US Food and Drug Administration for the 50 drugs, biologics, and drug classes that were commonly identified by 3 drug information compendia--Clinical Pharmacology, ePocrates(®), and Micromedex(®)--and the warfarin US prescribing information (PI) as having an interaction with warfarin. The PI of each product was assessed for possible mention of an interaction with warfarin. The data were collected and tabulated by 1 investigator. A clinical investigator evaluated the data for accuracy and consistency. Unresolved issues were discussed with a third investigator and decided by consensus. The interaction listings were compared to determine similarities, differences, and inconsistencies and analyzed by 5 investigators. RESULTS: Of the labeling for 73 products evaluated, 62 (85%) included mention of an interaction with warfarin. Those failing to mention the warfarin interaction were for older generic drugs or influenza vaccine. Among the labels listing an interaction with warfarin, the location of the information, the terminology used, and the inclusion of evidence for the interaction was inconsistent . When considering the PI for all 73 products, Fleiss' kappa coefficient (κ = 0.467) suggested moderate concordance according to the method of Landis and Koch. CONCLUSION: This assessment of official US product labeling for 50 drugs, biologics, and drug classes known to interact with warfarin, comprising 73 distinct agents, found that 15% failed to mention the interaction, even though the interaction was mentioned in the warfarin labeling.
File Format	HTM / HTML
ISSN	01492918
Issue Number	1
Volume Number	33
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2011-01-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Anticoagulants Adverse Effects Drug Interactions Drug Labeling Standards Warfarin Drugs, Generic Humans Terminology As Topic United States United States Food And Drug Administration Journal Article
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

FDA works toward product naming, packaging guidance.

Safety labeling on generic drugs is inconsistent, study says.

FDA approves first generic enoxaparin product.

US FDA patient-reported outcome guidance: great expectations and unintended consequences.

Some patients may receive too much information about prescriptions.

First oral warfarin alternative approved in the US.

Discontinued drugs in 2010: cardiovascular drugs.

Judicial developments in the US Hatch-Waxman infringement safe harbor.

Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.

Similar Documents

Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

FDA works toward product naming, packaging guidance.

Safety labeling on generic drugs is inconsistent, study says.

FDA approves first generic enoxaparin product.

US FDA patient-reported outcome guidance: great expectations and unintended consequences.

Some patients may receive too much information about prescriptions.

First oral warfarin alternative approved in the US.

Discontinued drugs in 2010: cardiovascular drugs.

Judicial developments in the US Hatch-Waxman infringement safe harbor.

Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.